APA (7th ed.) Citation

S, V., N, D., NJ, S., D, E., Q, Z., L, Y., . . . M, d. L. (2026). Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. Blood cancer discovery. https://doi.org/10.1158/2643-3230.BCD-26-0186

Chicago Style (17th ed.) Citation

S, Vasu, et al. "Safety and Clinical Outcomes of a First-in-human Trial of Point-of-care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22." Blood Cancer Discovery 2026. https://doi.org/10.1158/2643-3230.BCD-26-0186.

MLA (9th ed.) Citation

S, Vasu, et al. "Safety and Clinical Outcomes of a First-in-human Trial of Point-of-care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22." Blood Cancer Discovery, 2026, https://doi.org/10.1158/2643-3230.BCD-26-0186.